To summarize the last article: GLP-1 medications are reshaping modern medicine because they target the gut-brain-metabolic axis that drives most chronic disease - not just weight loss, but cardiovascular disease, heart failure, kidney disease, neurodegeneration, fatty liver, and systemic inflammation
Injection-Site Reactions: Mild redness, swelling, or discomfort may occur at the injection site
Functional cure is now an attainable target in CHB, and the emerging novel therapeutics will revolutionize CHB management
Common Mistakes We See Researchers Make Our team consults with labs all the time, and we see the same handful of mistakes derail otherwise well-planned research
Our platform connects individuals with licensed providers who can determine if these options are appropriate for their specific health profile
Ongoing trials aim to clarify: Cardiovascular safety Long-term weight durability Role in prediabetes and non-diabetic populations Comparison to semaglutide and tirzepatide Until then, we continue to emphasize current best practices: lifestyle support, personalized nutrition, advanced lipid testing, and thoughtful pharmacotherapy
